About Scott

Scott M. Rocklage, PhD joined 5AM Ventures in 2003 as a Venture Partner and became a Managing Partner in 2004. Dr. Rocklage has over three decades of healthcare management experience with strategic leadership responsibilities that led to FDA approval of three U.S. New Drug Applications (Omniscan™, Teslascan® and Cubicin®), and he has entered multiple drug candidates into clinical trials. Dr. Rocklage has served as Chairman and CEO of Cubist Pharmaceuticals, President and CEO of Nycomed Salutar, and has also held various R&D positions at Salutar and Catalytica. Dr. Rocklage formerly served as Board Chairman of Relypsa (NASDAQ: RLYP) and and Novira (acquired by Johnson & Johnson). He currently serves as Board Chairman of Rennovia, Kinestral, and Cidara (NASDAQ: CDTX) as well as on the Boards of Epirus (NASDAQ: EPRS) and Pulmatrix (NASDAQ: PULM). Dr. Rocklage was formerly Executive Chairman of Ilypsa (acquired by Amgen), Miikana (acquired by EntreMed), Semprus (acquired by Teleflex). Dr. Rocklage received his B.S. in Chemistry from the University of California, Berkeley and his PhD in Chemistry from the Massachusetts Institute of Technology (MIT) where he conducted research in the laboratory of Richard R. Schrock (Nobel Prize in Chemistry in 2005). He is an inventor or co-inventor on over 30 U.S. patents and greater than 100 peer-reviewed publications. Dr. Rocklage is based in the Boston, MA office.